Retinopathy - Pipeline Review, H1 2014

Description: Retinopathy - Pipeline Review, H1 2014

Summary

Global Markets Direct's, 'Retinopathy - Pipeline Review, H1 2014', provides an overview of the Retinopathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinopathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Retinopathy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Retinopathy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Retinopathy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Retinopathy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Retinopathy pipeline depth and focus of
Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Retinopathy Overview 6
Therapeutics Development 7
Pipeline Products for Retinopathy - Overview 7
Pipeline Products for Retinopathy - Comparative Analysis 8
Retinopathy - Therapeutics under Development by Companies 9
Retinopathy - Therapeutics under Investigation by Universities/Institutes 10
Retinopathy - Pipeline Products Glance 11
Early Stage Products 11
Retinopathy - Products under Development by Companies 12
Retinopathy - Products under Investigation by Universities/Institutes 13
Retinopathy - Companies Involved in Therapeutics Development 14
GTx, Inc. 14
Affichem 15
SIIF S.p.A 16
TWi Pharmaceuticals, Inc. 17
Biomar Microbial Technologies 18
Retinopathy - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Drug Profiles 27
SF-106 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
AC-301 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Beta-LGND2 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
IB-12A157 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Mutants Of Pigment Epithelium Derived Factor - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
AF-243 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
SF-113 - Drug Profile 34
Product Description 34
Mechanism of Action 34
List of Tables
Number of Products under Development for Retinopathy, H1 2014 7
Number of Products under Development for Retinopathy - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Early Stage Development, H1 2014 11
Products under Development by Companies, H1 2014 12
Products under Investigation by Universities/Institutes, H1 2014 13
Retinopathy - Pipeline by GTx, Inc., H1 2014 14
Retinopathy - Pipeline by Affichem, H1 2014 15
Retinopathy - Pipeline by SIFI S.p.A, H1 2014 16
Retinopathy - Pipeline by TWi Pharmaceuticals, Inc., H1 2014 17
Retinopathy - Pipeline by Biomar Microbial Technologies, H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 26
Retinopathy - Dormant Projects, H1 2014 35
Retinopathy - Discontinued Products, H1 2014 36

List of Figures
Number of Products under Development for Retinopathy, H1 2014 7
Number of Products under Development for Retinopathy - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 11
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23
Number of Products by Top 10 Molecule Type, H1 2014 25
Number of Products by Stage and Top 10 Molecule Type, H1 2014 26
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Retinopathy - Pipeline Review, H1 2014
Web Address: http://www.researchandmarkets.com/reports/2878159/
Office Code: SCD2ILET

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
  Account number 833 130 83
  Sort code 98-53-30
  Swift code ULSBIE2D
  IBAN number IE78ULSB98533083313083
  Bank Address Ulster Bank,
  27-35 Main Street,
  Blackrock,
  Co. Dublin,
  Ireland.

If you have a Marketing Code please enter it below:

  Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World